VPC
PRAX icon

Vestal Point Capital’s Praxis Precision Medicines PRAX Stock Holding History

Vestal Point Capital’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-440,000
Closed -$18.2M – 84
2024
Q2 		$18.2M Buy
440,000
+230,000
+110% +$10.9M 1.36% 25
2024
Q1 		$12.8M Buy
+210,000
New +$9.42M 1.06% 26

Other funds holding PRAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vestal Point Capital's PRAX Position: Q3 2024 in Review

Vestal Point Capital sold out of Praxis Precision Medicines (PRAX) in Q3 2024, closing a stake of 440,000 shares — an estimated $18.2M sold.

Vestal Point Capital first reported a position in PRAX in Q1 2024 and held it in 2 quarters. The position peaked at $18.2M in Q2 2024. 134 funds tracked by Wall St. Rank hold PRAX as of Q3 2024.

  • Vestal Point Capital reported no remaining Praxis Precision Medicines position as of Q3 2024 after selling out during the quarter.
  • Vestal Point Capital sold 440,000 Praxis Precision Medicines shares in Q3 2024, an estimated $18.2M.
  • Vestal Point Capital first reported a position in Praxis Precision Medicines in Q1 2024 and held it in 2 quarters.
  • Vestal Point Capital's Praxis Precision Medicines position peaked at $18.2M in Q2 2024.
  • 134 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2024.

Based on Vestal Point Capital's 13F filing for Q3 2024, filed 14 Nov 2024.